E.D. Drugs Causing Amnesia?
There have always been some concerns about side-effects from drugs that treat erectile dysfunction or E.D. Some are sudden blood pressure drops, hearing loss, and some are erections lasting four hours or more. There are also other side-effects, but the newest may have a new twist: TEMPORARY AMNESIA!
A labeling approval change was approved this month from the FDA that will also list amnesia as one of the side-effects in many erectile dysfunction drugs from major pharmaceutical companies. While this is a rare condition, it is called “transient global amnesia.” Here are the companies with changes:
- Pfizer Inc. (NYSE: PFE) for Viagra
- Eli Lilly & Co. (LLY) for Cialis.
After looking around the news and doing some back-dating, it looks like the FDA already made some label changes in Bayer’s Levitra, marketed in the U.S. by GlaxoSmithKline (NYSE: GSK) and
Schering-Plough (NYSE: SGP). You can see the notes on WebMD here.
What is odd is that it is not even clear and doesn’t seem to have been proven that E.D. drugs are responsible for the temporary amnesia. As most E.D. users are older in age and/or because so much is tied to blockage, it might even be other issues entirely. Over that we can not speculate, or are last refraining from it. The drug companies haven’t said that there is a definite answer either.
Think of the good news though. This could become a great excuse builder in the world. Maybe the big head isn’t the big thinker for men after all. This might also be the best argument ever that two-fers are crucial so that you are sure to remember what you did.
“Honey, I know those pictures are proof I was caught cheating. But I can’t remember it!!!!!”
That’s about it, because any more might be inappropriate for a business site.
Have a good weekend, even you don’t remember it all.
JON C. OGG
AUGUST 22, 2008
Novadel Looking to Leave Pennyland (NVD, HNAB)
Novadel Pharma (AMEX: NVD) shares look ripe for the picking at these price levels, so much so that insiders can’t keep their hands off them.
The specialty pharmaceutical company develops oral spray versions of drugs already on the market, and has strong co-agreements in North America and Europe, including rumors of a potential oral spray formulation of Viagra in collaboration with Pfizer.
Despite the numerous products in development, strong cash position and relatively low debt the stock has been hurt substantially ever since its U.S. launch of Zensana was delayed after Hana Biosciences (NASDAQ: HNAB) had experienced manufacturing issues. The stock plummeted to a year low $0.16 per share, placing the stock deep into Pennyland.
But the company is moving forward with its plans, and continues to make strong collaborate and licensing agreements, including a manufacturing and marketing agreement with European BioAlliance Pharma for its anti-emetic oral spray formulation Ondansetron announced just two days ago. The stock was up to $0.30 and higher last week and now sits at $0.34.
Insiders continue to buy, and have been doing so ever since the stock went sub-$1.00 back in August of 2007. This is a strong signal that the company’s stock could be on its way out of Pennyland. If not, there could still be plenty of room to run from here.
Dr. Hisham S. Ayoub, DMD
May 27, 2008
Latest from 247Wallst.com- Former HP CEO Mark Hurd May Join Oracle
- The Unusual Suspects for the Week Ahead (BKS, BRCD, CSKI, CIEN, FNFG, NAL, GENZ, SNY, LULU, ID, NFLX, NE, PBR, RTN, SKS, TTWO, THQI, CALL)
- Krispy Kreme Is Back
- The Ten Greatest Labor Strikes in American History
- Closing Prop-Trading, Fiduciary Neglect (JPM, GS, BAC, C, MS)
- Latest from VSInvestor
